Molecular Cytogenetics Market Analysis with Key Players, Trends and Future Scope
The global molecular cytogenetics market accumulated $1.8 billion revenue in 2017, and it is projected to attain a CAGR of 9.9% during the forecast period (2018–2023). The increasing popularity of pharmacogenomics in drug development and personalized disease management, advancements in cytogenetic techniques, and employment of these techniques in detecting chromosomal abnormalities are influencing the market growth. With the growing number of cytogenetic abnormalities, cases of cancer, and drugs becoming redundant in the treatment of diseases, a more robust technique is needed for determining the cause of and managing such conditions.
Molecular cytogenetics is the branch of genetics that deals with the study of chromosomal structure, its location and function within a cell, and the detection of genetic diseases. It utilizes techniques such as comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and karyotyping in various applications of biology and medicine. The market is segmented by technology, application, end-user, geography, and offering. On the basis of technology, the market is subdivided into FISH, IHC, CGH, karyotyping, and others. The market for FISH is expected to grow at a CAGR of 10.1% during the forecast period.
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=molecular-cytogenetics-market
The CGH subdivision is further classified into standard CGH and array-based CGH, of which array-based CGH held 55.4% share in the molecular cytogenetics market in 2017. In the application segment, the market has genetic disorders, cancer, and personalized medicine as its categories. In 2017, cancer was the largest application of molecular cytogenetics, accumulating a market share of 41.9%. This is credited to the increasing prevalence of cancer and the growing focus of research groups on developing diagnostic tools for it and other genetic disorders.
Another driving factor for this market is the developments in the field of pharmacogenomics and pharmacogenetics. With conventional treatments for cancer and many other chronic diseases becoming redundant, new avenues are being explored to find effective treatment methods. The field of pharmacogenomics has helped in tackling certain roadblocks in disease management. It has facilitated the understanding of the why’s and how’s of variable response to the same drug in people with the same medical condition, thereby driving the growth of the molecular cytogenetics market.
Thus, the market is set to grow during the forecast period owing to the advancements in technology in the field of biology and medicine.
